Revium Rx Statistics
Total Valuation
Revium Rx has a market cap or net worth of 31.58 million. The enterprise value is 25.92 million.
| Market Cap | 31.58M |
| Enterprise Value | 25.92M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Revium Rx has 60.73 million shares outstanding. The number of shares has increased by 90,590.53% in one year.
| Current Share Class | 60.73M |
| Shares Outstanding | 60.73M |
| Shares Change (YoY) | +90,590.53% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 56.70% |
| Owned by Institutions (%) | n/a |
| Float | 26.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.63 |
| P/TBV Ratio | 8.21 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.53 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -18.21 |
Financial Position
The company has a current ratio of 9.39, with a Debt / Equity ratio of 0.00.
| Current Ratio | 9.39 |
| Quick Ratio | 8.90 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -1,827.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -18.83% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -413,600 |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +73.33% in the last 52 weeks. The beta is -1.19, so Revium Rx's price volatility has been lower than the market average.
| Beta (5Y) | -1.19 |
| 52-Week Price Change | +73.33% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 0.47 |
| Relative Strength Index (RSI) | 100.00 |
| Average Volume (20 Days) | 1 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.09 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.66M |
| Pretax Income | -3.49M |
| Net Income | -2.07M |
| EBITDA | -3.65M |
| EBIT | -3.66M |
| Earnings Per Share (EPS) | -0.03 |
Balance Sheet
The company has 4.93 million in cash and 1,000 in debt, giving a net cash position of 4.93 million or 0.08 per share.
| Cash & Cash Equivalents | 4.93M |
| Total Debt | 1,000 |
| Net Cash | 4.93M |
| Net Cash Per Share | 0.08 |
| Equity (Book Value) | 19.41M |
| Book Value Per Share | 0.31 |
| Working Capital | 4.65M |
Cash Flow
In the last 12 months, operating cash flow was -1.42 million and capital expenditures -3,000, giving a free cash flow of -1.42 million.
| Operating Cash Flow | -1.42M |
| Capital Expenditures | -3,000 |
| Free Cash Flow | -1.42M |
| FCF Per Share | -0.02 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Revium Rx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -90,590.53% |
| Shareholder Yield | n/a |
| Earnings Yield | -6.55% |
| FCF Yield | -4.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 9, 2020. It was a reverse split with a ratio of 0.002.
| Last Split Date | Dec 9, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.002 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |